HomeTest MenuSTI Panel — Women
Female STI Screening · 9-Target Multiplex

Answer Every Question in One Swab.

Nine female-specific targets resolved in a single swab — chlamydia, gonorrhea, trich, Mgen, HSV-1/2, syphilis, chancroid, and Gardnerella — reported per-target in 24–48 hours.

The Women's STI Bench
0
Targets, Female-Specific
0
Vaginal Swab Covers All
Gardnerella
Included as Standard
0
Hours to Portal
The clinical problem
Screening women requires female-specific coverage.

Generic STI panels treat male and female anatomy as interchangeable. They aren't. A woman presenting with discharge or dysuria needs Trichomonas, Mycoplasma genitalium, and Gardnerella resolved in the same draw — not three separate send-outs across three different labs.

Our female panel covers nine targets that map directly to the differential a women's-health provider is actually working through, with PCR-grade sensitivity and 24–48 hour turnaround.

By the Numbers

The clinical weight behind this panel.

Industry statistics from public-health bodies and peer-reviewed literature — context for why this testing matters.

20M+
new STIs diagnosed in the U.S. each year

Half occur in people aged 15–24.

Source · CDC STI Surveillance
1 in 5
U.S. adults has a sexually transmitted infection on any given day
Source · CDC 2021
10–15%
of untreated chlamydia progresses to PID

PID is a leading preventable cause of infertility and ectopic pregnancy.

Source · CDC
70%
of chlamydia infections in women are asymptomatic

Screening — not symptoms — drives diagnosis.

Source · CDC

Figures reflect publicly reported epidemiology and clinical literature for context only. They are not performance claims for the Chaseville Labs assay. See individual citations from the U.S. Centers for Disease Control and Prevention, World Health Organization, National Institutes of Health, and peer-reviewed journals.

What This Panel Diagnoses

Conditions, syndromes & infections covered.

The clinical scenarios where this panel is the right call — built around the differential your providers are actually working through.

Reportable Bacterial STIs

3
Chlamydia (Chlamydia trachomatis)

The most common reportable STI in the U.S. — asymptomatic in up to 70% of women.

Clinical Impact ·Untreated chlamydia drives pelvic inflammatory disease (PID), ectopic pregnancy, and infertility. Rapid detection enables partner notification and same-week treatment.
Gonorrhea (Neisseria gonorrhoeae)

Cervicitis, PID, disseminated gonococcal infection, and neonatal conjunctivitis risk in pregnancy.

Clinical Impact ·Drug-resistant gonorrhea is rising — confirmed detection drives CDC-aligned dual therapy.
Mycoplasma genitalium (Mgen)

Emerging cause of cervicitis, PID, and urethritis — historically under-diagnosed.

Clinical Impact ·Detection prompts macrolide-resistance follow-up testing; standard azithromycin increasingly fails.

Vaginitis & Reproductive Health

3
Trichomoniasis (Trichomonas vaginalis)

Causes vaginitis, dyspareunia, and increases HIV acquisition risk.

Clinical Impact ·Wet-mount microscopy misses 40–50% of infections — molecular catches what the eye can't.
Bacterial Vaginosis support (Gardnerella vaginalis)

Supports BV diagnosis when combined with clinical picture and Lactobacillus depletion.

Group B Strep colonization (GBS / S. agalactiae)

Vaginal/rectal colonization during pregnancy.

Clinical Impact ·Detection guides intrapartum penicillin prophylaxis to prevent neonatal sepsis and meningitis.

Genital Herpes

2
HSV-1 — Genital Herpes

Increasingly the dominant cause of new genital herpes diagnoses, especially in younger patients.

Clinical Impact ·Type-specific result guides recurrence counseling — HSV-1 genital recurs less often than HSV-2.
HSV-2 — Genital Herpes

Classic cause of recurrent genital ulcers; higher transmission and shedding risk.

Clinical Impact ·Confirms diagnosis for suppressive therapy decisions (daily valacyclovir / acyclovir).
Complete Target List

9 targets, resolved from a single specimen.

Each organism below is reported individually as Detected, Not Detected, or Inconclusive — grouped here by pathogen class for clinical scanability.

Targets

8 targets
Chlamydia trachomatisNeisseria gonorrhoeaeTrichomonas vaginalisMycoplasma genitaliumGardnerella vaginalisHSV-1HSV-2Streptococcus agalactiae (GBS)
Why Molecular

Culture was built for a different century.

Multiplex real-time PCR resolves what culture and rapid antigen miss — fastidious organisms, polymicrobial infections, viruses, and resistance markers — from a single specimen.

Conventional
The Old Way

Culture & rapid antigen

  • 3–5 days
    Patient empirically treated before any answer arrives
  • Misses fastidious & viral organisms
    No growth ≠ no infection
  • Single-organism bias
    Polymicrobial infections under-reported
  • No resistance data
    Susceptibilities arrive a day later, if at all
  • Specimen-quality dependent
    Pre-treated patients culture negative
Multiplex PCR
The CRL Way

STI Panel — Women on Bio-Rad CFX384

  • 24–48 hours
    Most reports back the next clinical day
  • 9 targets, one run
    Bacterial, viral, fungal, and parasitic in a single multiplex
  • Detects what culture can't
    Fastidious organisms, viruses, and polymicrobial infections, all reported individually
  • Validated LDT
    CLIA-certified, internally controlled, per-target Detected / Not Detected reporting
Primary Specimen
Urine, vaginal swab
Collection Container
Sterile collection device per specimen type
Volume
Per collection protocol
Storage
2–8°C up to 72 hours
Transport
Pre-paid FedEx Priority Overnight
Stability
Validated per storage condition
Chain of Custody
Barcoded, temperature-logged in transit
Result Format

Per-target results, with clinical context.

Every analyte is reported individually as Detected, Not Detected, or Inconclusive. What a Detected result means clinically depends on which category the target falls into:

Targets
Chlamydia trachomatisNeisseria gonorrhoeaeTrichomonas vaginalisMycoplasma genitaliumGardnerella vaginalisHSV-1HSV-2Streptococcus agalactiae (GBS)
If Detected

Each Detected result maps to a specific actionable diagnosis. CT, NG, Mgen, and Trichomonas are treated per CDC guidance; Gardnerella supports a BV diagnosis in the right clinical picture; HSV-1/2 typing guides recurrence counseling and suppression decisions; GBS detection informs intrapartum prophylaxis.

Qualitative multiplex real-time PCR (Bio-Rad CFX384)
Turnaround: 24–48 hours